Abstract 【Objective】To explore the application value of T1 mapping quantified with cardiac MR (CMR) in the evaluation of left ventricular systolic function and myocardial fibrosis in severe aortic regurgitation (AR) patients. 【Methods】28 patients with severe AR in our hospital from January 2018 to November 2020 and 30 subjects at the same period for physical examination were selected as study group and control group respectively, and they were given cardiac magnetic resonance (CMR) and T1 mapping. The left ventricular myocardial mass (LVMM), left ventricular end diastolic volume index (LVEDVi), left ventricular end systolic volume index (LVESVi), left ventricular stroke volume index (LVSVi) , left ventricular ejection fraction (LVEF) , initial T1 value, enhanced T1 value and ECV value were compared between the two groups,and Pearson coefficient for correlation analysis. 【Results】 The LVMM, LVEDVi, LVESVi and LVSVi in study group were higher than those in control group (P<0.05); the LVEF in study group was lower than those in control group (P<0.05); the initial T1 value and ECV in study group were higher than those in control group (P<0.05); Pearson Correlation analysis showed that the initial T1 value and ECV value were negatively correlated with LVEF (P<0.05). 【Conclusion】T1 mapping can reflect the diffuse fibrosis of the myocardium in patients with severe AR, which is related to early cardiac remodeling and left ventricular systolic dysfunction to identify subclinical myocardial changes caused by volume overload before clinical symptoms appear.
[1] NISHIMURA R A. 2014 AHA/ACC guideline for the management of patients with valvular heart disease: executive summary: a report of the american college of cardiology/american heart association task force on practice guidelines[J].J Am Coll Cardiol,2014,63(22): 2438-2488.
[2] PODLESNIKAR T. Cardiovascular magnetic resonance imaging to assess myocardial fibrosis in valvular heart disease[J].Int J Cardiovasc Imaging,2018,34(1): 97-112.
[3] 陈秀玉, 赵世华. 2017 SCMR心脏磁共振参数定量技术专家共识解读[J].磁共振成像,2018,9(5): 368-373.
[4] AZEVEDO C F, NIGRI M, HIGUCHI M L, et al. Prognostic significance of myocardial fibrosis quantification by histopathology and magnetic resonance imaging in patients with severe aortic valve disease[J].J Am Coll Cardiol,2010,56(4): 278-287.
[5] MESSROGHLI DANIEL R, MOON JAMES C, FERREIRA VANESSA M, et al. Clinical recommendations for cardiovascular magnetic resonance mapping of T1, T2, T2* and extracellular volume: A consensus statement by the Society for cardiovascular magnetic resonance (SCMR) endorsed by the european association for cardiovascular imaging (EACVI)[J].J Cardiovasc Magn Reson,2017,19(1):75.
[6] NISHIMURA R A, OTTO C M, BONOW R O, et al. 2017 AHA/ACC Focused Update of the 2014 AHA/ACC Guideline for the management of patients with valvular heart disease: a report of the american college of cardiology/american heart association task force on clinical practice guidelines[J].Circulation,2017,135(25): e1159-e1195.
[7] 孟庆江, 张双林, 郑先杰,等. DE-CMR在主动脉关闭不全患者手术预后评估中的应用分析[J].中国CT和MRI杂志,2017,15(8): 146-148.
[8] EDWARDS N C, MOODY W E, YUAN M, et al. Quantification of left ventricular interstitial fibrosis in asymptomatic chronic primary degenerative mitral regurgitation[J].Circ Cardiovasc Imaging,2014,7(6):946-953.
[9] ROBINSON A A, CHOW K, SALERNO M. Myocardial T1 and ECV Measurement: Underlying Concepts and Technical Considerations[J].JACC Cardiovasc Imaging,2019,12(11 Pt 2): 2332-2344.
[10] SPARROW P, MESSROGHLI D R, REID S,et al. Myocardial T1 mapping for detection of left ventricular myocardial fibrosis in chronic aortic regurgitation: pilot study[J].AJR Am J Roentgenol,2006,187(6): W630-635.
[11] DE MEESTER DE RAVENSTEIN C, BOUZIN C, LAZAM S, et al. Histological Validation of measurement of diffuse interstitial myocardial fibrosis by myocardial extravascular volume fraction from Modified Look-Locker imaging (MOLLI) T1 mapping at 3T[J].J Cardiovasc Magn Reson,2015,17(1):48.
[12] 郑育聪,陆敏杰,尹刚,等. 心血管MR T1 mapping/iECV定量分析在主动脉瓣关闭不全评价中的价值[J].中华血液学杂志,2021,55(3): 269-275.
[1]
. [J]. JOURNAL OF CLINICAL RESEARCH, 2022, 39(5): 762-764.
2022, Vol. 39 
